

08th October 2020

DIAPATH SAFECAPSULE CHOSEN BY THE MATERNITY DEPARTMENT OF THE LA ROCHELLE HOSPITAL IN FRANCE

The maternity ward of the La Rochelle-Ré-Aunis hospital group has been committed since 2018 to a sustainable approach to reducing exposure to chemicals to eliminate the risk of endocrine disruptors.

Formaldehyde, a colorless and irritating gas, is the fixative par excellence used in Pathological Anatomy laboratories: easily available, at low cost, does not alter, allows the preservation of cell morphology, guarantees standardized protocols for histochemical, immunohistochemical and molecular investigation. However, formaldehyde has been reclassified as a carcinogen and mutagen. To date, there is no fixative available that is a valid alternative to formaldehyde.

To eliminate or minimize the risk of exposure to formalin and its vapors in a free environment, Diapath has put on the market a device for the collection, storage and transport of biological samples: SafeCapsule.

At the hospital in La Rochelle (a town in southwestern France), environmental health has been a daily concern for several years. To ensure the healthiest possible environment for newborns, the maternity ward decided in February 2018 to commit, together with other hospitals in the region, to a chemical risk reduction project. Initial goal: to take stock of products harmful to health in daily hospital life. "We had to find very precise information on the products used in the services that the maternity hospital works with every day," explains the project representative. Another action taken was to stop the manipulation of formalin in the operating room, "Our principle is to change practices while we operate. Sometimes these are small changes but, together, they make a difference!"

For this reason, Diapath SafeCapsule device was chosen by the French clinic Groupe Hospitalier De La-Rochelle-Re-Aunis for the project "1400 JOURS POUR BEBE- 1400 DAYS FOR A BEBE". SafeCapsule guarantees total safety in the maternity ward by eliminating the risk deriving from endocrine disruptors for a correct neonatal development.

DIAPATH S.p.A. After the preliminary step concerning the evaluation of the different financial opportunities promoted by the European Commission, Diapath has been chosen for the Horizon 2020 grant. Founded in 1997, Diapath moves its first step as distributor of reagents and medical instruments regarding Anatomic Pathology. In few years Diapath has changed, becoming an international brand leading the research and creating high-tech instrument highly appreciated by hospitals and private clinics.

INFO
www.diapath.com/press

Marketing Corporate
marketing@diapath.com
